Variables	P (n=12)	A (n=16)
Age, years [min; max]	13.2 [12.1;15.6]	14.3 [12;16.5]
Female, n [%]	7 [58.3]	8 [50.0]
Male, n [%]	5 [41.7]	8 [50.0]
Tanner Stage 1 Female, %	0.0	0.0
Tanner Stage 2 Female, %	0.0	12.5
Tanner Stage 3 Female, %	71.4	25.0
Tanner Stage 4 Female, %	14.3	50.0
Tanner Stage 5 Female, %	14.3	12.5
Tanner Stage 1 Male, %	0.0	0.0
Tanner Stage 2 Male, %	40.0	28.6
Tanner Stage 3 Male, %	60.0	42.9
Tanner Stage 4 Male, %	0.0	28.6
Tanner Stage 5 Male, %	0.0	0.0
Family History DMT2 ,n [%]	7 [58.3]	11 [68.8]
Family History C-vx, n [%]	5 [41.7]	9 [56.2]
Pubertal stage according to the criteria of Tanner. Family history for diabetes mellitus type 2 (DMT2) and cardiovascular (C-vx) diseases in first degree relatives. P, placebo group. A, atorvastatin-treated group Table S1, supplementary data: Pubertal stage and family history for diabetes mellitus type 2 and cardiovascular diseases in first degree relatives

		P (n=12) Median [min; max]	A (n=16) Median [min; max]
BMI, kg/m2	V1	30.1 [27.2;38.9]	33.1 [30.1;43.9]
	V2	31 [27.1;41.7]	32.7 [29.4;46.5]
	V3	31.5 [25.7;42.6]	34.3 [29.8;39.8]
HOMA	V1	3.1 [1.4;6.9]	3.2 [0.4;5.4]
	V2	4.1 [2.6;9.8]	3.9 [1.9;9.9]
	V3	4.8 [2.1;7]	4.5 [2.5;8.2]
MCP-1, pg/mL	V1	137.3 [80.5;358.1]	172.2 [44.6;280.4]
	V2	169.8 [96.7;352]	141.6 [46.4;280.6]
	V3	189.9 [91;237.6]	126.6 [28;423.8]
IL-6, pg/mL	V1	0	0
	V2	0	0
	V3	0	0
IP-10, pg/mL	V1	4.3 [1.9;9.5]	2.6 [1.3;12]
	V2	4 [1.9;7.5]	3.5 [1.3;18]
	V3	5 [2.1;31.5]	4.8 [2.5;22]
IL1-Ra, pg/mL	V1	1330.2 [780.5;2690.4]	1219.5 [558.9;2956.1]
	V2	1255.6 [753.1;2741.1]	1269 [835.1;2436.3]
	V3	1425.9 [673.1;7894.3]	1176.4 [522.7;4017]
IL-10, pg/mL	V1	0	0
	V2	0	0
	V3	0	0
CRP, mg/L	V1	1.4 [0.5;5.6]	2.7 [0.5;18.5]
	V2	1.8 [0.5;9.8]	3.1 [1;16.8]
	V3	1.8 [1;19.7]	3.2 [1;13.3]
Table S2, supplementary data: BMI, HOMA, cytokines levels, CRP for the two groups at Visit 1 (V1), Visit 2 (V2) and Visit 3 (V3)

		P (n=12) Median [min; max]	A (n=16) Median [min; max]
PT, %	V1	96.5 [84;100]	100 [77.3;100]
	V2	100 [86;100]	100 [66;100]
	V3	99 [84;100]	100 [82;100]
aPTT, sec	V1	26.6 [23.5;30]	26.4 [24;31.2]
	V2	26.8 [24;28.7]	26 [23.3;32.6]
	V3	26 [22.5;29.3]	25.6 [22.9;30.7]
Fibrinogen, g/L	V1	3.6 [2.7;4.4]	3.6 [2.6;5.6]
	V2	4.2 [3.2;5.2]	4.4 [2.2;7.1]
	V3	4.1 [2.8;5.7]	3.9 [3;6.2]
D-Dimers, ng/mL	V1	267 [124;665]	279 [131;627]
	V2	244.5 [161;490]	270.5 [156;607]
	V3	336 [132;436]	265.5 [87;562]
ETP, mA	V1	366.2 [323.9;422.2]	397.1 [329.4;468.3]
	V2	376.2 [334.8;458.1]	384.9 [329.3;448.6]
	V3	389.8 [346;447.2]	400.2 [364.2;485.2]
tLag, sec	V1	16.6 [15.2;18.1]	16.4 [12.9;20.4]
	V2	16.6 [14.4;18.3]	17 [14;21.1]
	V3	16.5 [14.2;19.3]	17.4 [14.3;21.4]
tMax, sec	V1	45.2 [37.6;58]	48.6 [25.6;66.2]
	V2	39 [33;46.4]	45.6 [33.3;55.2]
	V3	46.1 [32.7;51.7]	47.2 [40.8;54.9]
cMax, nM	V1	144.1 [127.1;161.7]	139.6 [127;183]
	V2	152.8 [133.3;170.4]	141.9 [124.2;170]
	V3	144.7 [133.4;153.8]	146.7 [128.4 ;168.8]
	V3	4.1 [2.7;4.8]	3.6 [2.6;4.8]
Table S3, supplementary data: Coagulation parameters for the two groups at Visit 1 (V1), Visit 2 (V2) and Visit 3 (V3)

		P (n=12) Median [min; max]	A (n=16) Median [min; max]
Cholesterol, mmol/L	V1	3.7 [3.1;4.7]	3.4 [2.6;5]
	V2	4.0 [3.1;5.2]	2.9 [2.1 ;4.9]
	V3	4.1 [2.7;4.8]	3.6 [2.6;4.8]
HDL, mmol/L	V1	1.0 [0.5;1.5]	0.95 [0.6;1.7]
	V2	1.0 [0.9;1.5]	1.1 [0.5;1.4]
	V3	1.0 [0.6;1.5]	1.1 [0.7;1.8]
LDL, mmol/L	V1	2.4 [1.6;3.2]	2.1 [1.2;3.4]
	V2	2.5 [2.0;3.2]	1.6 [1.0;3.4]
	V3	2.7 [1.9;3.2]	2.2 [1.3;3.1]
Tg, mmol/L	V1	0.8 [0.49;1.6]	0.7 [0.5;2.1]
	V2	0.8 [0.3;1.1]	0.6 [0.4;1.4]
	V3	0.9 [0.4;2.4]	0.7 [0.4;1.7]
Table S4, supplementary data: Lipid profile for the two groups at Visit 1 (V1), Visit 2 (V2) and Visit 3 (V3) Tables S2, S3, S4 supplementary data Data are reported as median values, with minimal and maximal values [min; max]. P, placebo group. A, atorvastatin-treated group. V1, Visit 1 at baseline. V2, Visit 2 after 16 weeks. V3, Visit 3, after 1 year. HOMA, homeostatic model assessment. MCP-1, monocyte chemoattractant protein 1. IL-6, interleukin-6. IP-10, jnterferon-g-inductible protein. IL1-Ra, interleukin-1 receptor antagonist. IL-10, interleukin-10. CRP, C-reactive protein. PT, prothrombin time. aPTT, activated partial thromboplastin time. ETP, endogenous thrombin potential. tLag, lag time. tMax, time to peak. cMax, peak value. HDL, High Density Lipoprotein. LDL, Low Density Lipoprotein. Tg, triglycerides. sec, seconds. mA, milli- absorbance units. 0 indicates values < 1 pg/mL (values below the detection level of 1 pg/mL)